Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Waverley Pharma Inc V.WAVE

Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. Its primary focus is the PARP-1 program and secondary focus is the generic oncology injectable market in European Union, the United Kingdom (UK) and North America. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited, which has granted it an exclusive territorial license to market and sell capecitabine in the UK and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Its generic oncology products include bortezomib and pemetrexed. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma.


TSXV:WAVE - Post by User

Post by Johnmecoon Feb 04, 2022 11:47am
282 Views
Post# 34397865

Email from Dr. Friesen

Email from Dr. Friesen
This is copy from yahoo Isaac's post From Dr. Friesen Both Pemetrexed and Bortezomib are scheduled for approval this summer. Waverley Pharma is presently working with GPOs and other buying groups to get contracts for both products this summer. Waverley Pharma has won some contracts in the UK and bidding on a number in the EU. So far the contracts have been relatively small and very low prices. Waverley Pharmas main interest has always been the USA, which has a much better pricing structure for generics and much higher volumes. As part of our negotiating, Reliance Life Sciences asked us to take on the some UK and EU countries. My focus is to grow the company and use the profits to acquire and develop other products. We have negotiated on a number but have been conserving cash to get to profitability. I appreciate your interest and am hopefully of significant activities to share with the market this summer.
<< Previous
Bullboard Posts
Next >>